The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.
People who experience diffuse thinning of their hair and how they cope with going swimming. People discussed wearing a swimming cap, making jokes out of it and accepting that it's genetics.
The conversation discusses creating a foam version of RU58841 for easier application on thick hair, comparing it to minoxidil foam. The user currently uses dutasteride, minoxidil, and needling for hair loss treatment.
HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.
The user experienced significant hair regrowth using 1mg finasteride daily and Rogaine minoxidil 5% foam twice a day, along with vitamin D supplementation. They also managed stress through lifestyle changes like exercise, quitting nicotine, and improving sleep.
User shared progress on hair regrowth using 1.25 mg finasteride daily, 5% minoxidil, and a 1.5 mm dermaroller twice a week, with no side effects. Users discussed shedding phases, application methods, and the necessity of continuous treatment to maintain results.
A user shared their one-year progress using finasteride and minoxidil for hair loss, showing significant improvement. They also mentioned using the medication inconsistently and considering changes to their shampoo routine.
The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.
Fluorescent lighting makes hair look thinner, causing concern about appearance. Some users consider treatments like DUT, while others share experiences of hair looking better in different lighting or conditions.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
Evan Fournier, an NBA player, experienced rapid hair loss despite using finasteride and minoxidil, showing that even wealthy individuals can struggle with hair loss. His teammates suggested he shave his head, highlighting the emotional impact of hair loss.
A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
Creatine may cause hair shedding and texture changes, with mixed user experiences. Combining creatine with finasteride doesn't always prevent these effects, possibly due to individual DHT sensitivity.
A 36-year-old man shared his 1.25-year progress using oral finasteride, oral minoxidil, RU58841, microneedling, nizoral, and LLLT for hair regrowth. He is thrilled with the results and considering a hair transplant for increased density.
RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
A user shared progress pictures showing hair improvement over 85 days using 1mg finasteride daily, 1ml minoxidil nightly, and weekly microneedling. Another user commented on the positive results and shared their own treatment hopes.
A user's progress with treating hair loss using 1mg finasteride per day, with reports of no noticeable side effects and positive results. Other users have shared their experiences with different treatments, such as Dutasteride and Minoxidil.
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
Using a combination of micro-needling and exosome injections as a potential treatment for male pattern baldness, which could result in 50% or more regrowth.
The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.
The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.
The user has been taking 0.5mg finasteride daily for 1.5 years, which has helped maintain and regrow some hair without side effects. They chose this dosage to reduce the risk of side effects and have not added minoxidil due to family heart issues and having a cat.
Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.